BrosMed Medical Co., Ltd. Announces CE Mark Approval of the Tri-Wedge PTA Scoring Balloon Dilatation Catheter
Release time:
2020-01-19
February 19th, 2020—BrosMed Medical Co., Ltd. announced CE Mark and launched its Tri-Wedge PTA Balloon Catheter. Tri-Wedge is a Percutaneous Transluminal Angioplasty (PTA) Scoring Balloon Dilatation Catheter, which ideal for Arteriovenous Fistula (AV) Shunt Scoring.
February 19th, 2020—BrosMed Medical Co., Ltd. announced CE Mark and launched its Tri-Wedge PTA Balloon Catheter. Tri-Wedge is a Percutaneous Transluminal Angioplasty (PTA) Scoring Balloon Dilatation Catheter, which is ideal for Arteriovenous Fistula (AV) Shunt Scoring.
Tri-Wedge PTA Scoring Balloon Dilatation Catheter achieves accurate annular fibrous, calcified plaque location and minimal balloon slippage. This balloon with trimetallic wires can reach lesions smoothly with an uniform vertical distribution. High efficient vertical extrusion to score the plaque with concentrated dilatation stress, low pressure and high safety dilatation reduces the vessel wall injury and incidence of restenosis.
“Tri-Wedge Peripheral balloon provides excellent crossing ability, high pressure and non-compliance. It was ideally designed in the treatment of complex lesions with significant calcification and fibrosis. It is believed this unique balloon design technology will make a difference to the PTA scoring balloon market.” said by Stephen Lee, Sr. vice president of BrosMed Medical Co., Ltd. “By continuously improving our balloon performance, we support the physicians to solve complex lesion cases”
For more product details and information, please contact your regional distributor and/or our direct sales force at sales@brosmed.com / cs@brosmed.com or +86 769 22892018 / +31 850 140901.
About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
BrosMed Medical product portfolio consists of Artimes™ PTCA, Apollo™ PTCA, Atropos™ 0.035 PTA, Minerva™ 0.018 PTA, Polux™ 0.014 PTA, Hermes™ NC 0.035 PTA, Achilles™ NC 0.018 PTA, Castor™ NC 0.014 PTA, Conger™ Hydrophilic coated wire and series of accessories.
Join Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announces Canadian Approval of RevoEdge™ High-Pressure Cutting Balloon
BrosMed Medical today announced Canadian regulatory approval of the RevoEdge™ High-Pressure Cutting Balloon Dilatation Catheter, expanding the company’s presence in North America and marking another milestone in the global commercialization of its specialty coronary portfolio.
2026-09-14
BrosMed Announced CE MDR Approval of VascuGlide™ Microcatheter System
June 15, 2026-BrosMed is pleased to announce that the VascuGlide™ Microcatheter System has received CE MDR certification, marking another significant milestone in the company's commitment to advancing peripheral intervention solutions.
2026-06-18
